
Last updated: 2026-09-13 06:18:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Eocene Ltd. (EOCN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $3.89, with a market capitalization of $4.10M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.66 to $4.88. This page covers its latest market performance, valuation, price trends and company information.
$4.10M | |
$4.00 | |
$4.88 | |
$3.66 | |
$4.03 | |
44.88K | |
118.44K | |
-- | |
$4.88 | |
$3.66 | |
-- | |
-- |
Eocene Ltd. (EOCN) last closed at $4.03 as of 2026-09-11 23:17:00, unchanged from the previous close of $4.03.
During the latest regular trading session, EOCN traded between $3.66 and $4.88, with a volume of 44.88K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Eocene Ltd. (EOCN) moved from $4.03 to $3.89, representing a decline of 3.57% ($0.14).
The stock traded between $3.66 and $4.88 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 118.44 thousand shares, -- versus the previous seven-day period, indicating -- trading activity.
Position in Range: 18.9%
EOCN is currently trading at $3.89, placing it 18.9% of the way from its 52-week low of $3.66 to its 52-week high of $4.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Eocene Ltd. (EOCN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.